# Pharmacogenetics of Naltrexone for Stimulant Abuse

> **NCT03226223** · PHASE2 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 18 (actual)

## Conditions studied

- Substance Use Disorders
- Methamphetamine Abuse

## Interventions

- **DRUG:** Intranasal Methamphetamine

## Key facts

- **NCT ID:** NCT03226223
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-15
- **Primary completion:** 2019-07-15
- **Final completion:** 2020-07-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226223, "Pharmacogenetics of Naltrexone for Stimulant Abuse". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03226223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*